Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Carboplatin 1167Cisplatin 889Pemetrexed 845pembrolizumab 622Paclitaxel 608Docetaxel 539Gemcitabine 428Radiotherapy 390Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 296durvalumab 264Drug Therapy 260osimertinib 236atezolizumab 224Radiosurgery 194Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 131Ipilimumab 129130-nm albumin-bound paclitaxel 124Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
CD3 Complex × Thoracic × Clear all
NCT00056537 2014-08-27

ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

Active Biotech AB

Phase 1 Completed
44 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Pancreatic Neoplasms

NCT00132379 2014-08-27

ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer

Active Biotech AB

Phase 1 Completed
13 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡